Bionik Laboratories (Bionik Laboratories) FCF Margin % : -151.10% (As of Mar. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Bionik Laboratories FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Bionik Laboratories's Free Cash Flow for the three months ended in Mar. 2023 was $-0.76 Mil. Bionik Laboratories's Revenue for the three months ended in Mar. 2023 was $0.50 Mil. Therefore, Bionik Laboratories's FCF Margin % for the quarter that ended in Mar. 2023 was -151.10%.

As of today, Bionik Laboratories's current FCF Yield % is 0.00%.

The historical rank and industry rank for Bionik Laboratories's FCF Margin % or its related term are showing as below:

BNKL' s FCF Margin % Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0
Current: -187.65

BNKL's FCF Margin % is not ranked
in the Healthcare Providers & Services industry.
Industry Median: 1.385 vs BNKL: -187.65

Bionik Laboratories FCF Margin % Historical Data

The historical data trend for Bionik Laboratories's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bionik Laboratories FCF Margin % Chart

Bionik Laboratories Annual Data

Trend

Dec14

Dec15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

FCF Margin %

Get a 7-Day Free Trial

-287.55

-428.43

-387.59

-326.53

-187.65

Bionik Laboratories Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
FCF Margin %	Get a 7-Day Free Trial															-722.51	-478.19	-196.50	-89.22	-151.10

Competitive Comparison of Bionik Laboratories's FCF Margin %

For the Medical Care Facilities subindustry, Bionik Laboratories's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bionik Laboratories's FCF Margin % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Bionik Laboratories's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Bionik Laboratories's FCF Margin % falls into.

Bionik Laboratories FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Bionik Laboratories's FCF Margin for the fiscal year that ended in Mar. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Mar. 2023 )	/	Revenue (A: Mar. 2023 )
	=	-3.387	/	1.805
	=	-187.65 %

Bionik Laboratories's FCF Margin for the quarter that ended in Mar. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2023 )	/	Revenue (Q: Mar. 2023 )
	=	-0.757	/	0.501
	=	-151.10 %

Bionik Laboratories FCF Margin % Related Terms

Thank you for viewing the detailed overview of Bionik Laboratories's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Bionik Laboratories (Bionik Laboratories) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Bionik Laboratories Corp (OTCPK:BNKL) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

80 Coolidge Hill Road, Watertown, MA, USA, 02472

Website

https://www.bioniklabs.com

Bionik Laboratories Corp is a healthcare company focused on improving the quality of life of millions of people with neurological or mobility impairments by combining artificial intelligence and innovative robotics technology to help individuals from hospital to home regain mobility, enhance autonomy, and regain self-esteem. The company uses artificial intelligence and machine learning technologies to make rehabilitation methods and processes smarter and more intuitive to deliver a greater recovery for patients with neurological or mobility impairments. Its products The InMotion ARM, and InMotion ARM/HAND are robotic therapies for the upper limbs.

Executives

Remi Gaston-dreyfus	director, 10 percent owner	46 RUE PIERRE CHARRON, PARIS I0 75008
Charles Matine	director	7 RUE GUSTAVE, FLAUBERT, PARIS I0 75017
Andre-jacques Auberton-herve	director, officer: Chairman	18 CHEMIN DE LA VIERGE NOIRE, LA TRONCHE I0 38700
Daniel Gonsalves	officer: Executive Vice President & CFO	80 COOLIDGE HILL ROAD, WATERTOWN MA 02472
Loren W. Wass	officer: See Remarks	34 HOG HILL ROAD, PEPPERELL MA 01463
Joseph R Martin	director
Audrey Thevenon	director	4500 WESTBROOK LANE, KENSINGTON MD 20895
Peter Gerald Malone	director
Russo Richard Paul Jr	officer: Chief Financial Officer	20 PLUNKETT WAY, TEWKSBURY MA 01876
Renaud Bertrand Maloberti	officer: Chief Commercial Officer	10 ACORN WAY, GEORGETOWN MA 01833
Timothy A. Mccarthy	officer: Chief Commercialization Office	C/O BIONIK, 483 BAY STREET, N105, TORONTO A6 M5G 2C9
Eric Michel Dusseux	director	1 RUE DU CAPOT, CALUIRE-ET-CUIRE I0 69300
Jules Marc Fried	officer: VP - U.S. Operations	C/O INTERACTIVE MOTION TECHNOLOGIES INC., 80 COOLIDGE HILL ROAD, WATERTOWN MA 02472
Hermano Igo Krebs	officer: Chief Science Officer	C/O INTERACTIVE MOTION TECHNOLOGIES INC., 80 COOLIDGE HILL ROAD, WATERTOWN MA 02472
Marc Mathieu	director	716 BROOKS AVENUE, VENICE CA 90291